Abstract:Objective: In this paper, we aim to show that the immunogenicity of the lyophilized human rabies vaccine (Vero cells) (investigational vaccine) developed by Dalian Aleph Biomedical Co., Ltd. in healthy participants aged 10–60 years old is non-inferior to the lyophilized PVRV (positive control) manufactured by Liaoning Chengda Biotechnology Co., Ltd. (Shenyang, China), and that its safety is clinically acceptable. Method: A total of 2776 participants were enrolled in this study and divided into four groups: a five-dose test group, a five-dose control group, a four-dose test group, and a four-dose control group. The patients in the four-dose groups (Zagreb) were vaccinated on Days 0 (two doses), 7 (one dose), and 21 (one dose), and those in the five-dose groups (Essen) were vaccinated on Days 0, 3, 7, 14, and 28 (one dose each). The rabies-virus-neutralizing antibody assay with the RFFIT was used to assess the immunogenicity, and the adverse events (AEs) and serious adverse events (SAEs) were identified and collated. Results: The positive seroconversion rate was up to 100% on Days 14 and 35/42 after vaccination following any procedures in pre-immunization antibody-negative participants, and the positive seroconversion rate and geometric mean concentration (GMC) of the test groups (Zagreb and Essen vaccination procedures) was not inferior to that of the control groups. On Day 7 after vaccination, the immunogenicity of the Zagreb procedure with two doses of the vaccine on Day 0 was superior to the Essen procedure with one dose of vaccine, that is, the former had a higher seroconversion rate and RVNA titer. The non-inferiority criterion of immunogenicity was met for the whole population, the population aged 10–18 years and ≥18 years, and the pre-immunization antibody-positive population. The incidences of all AEs, solicited AEs, and unsolicited AEs in both groups were not statistically significant, and no vaccination-related SAEs were observed. Conclusion: The investigated vaccine is safe, its immunogenicity is non-inferior to that of the control vaccine, and the efficacy of the Zagreb procedure is superior to that of the Essen procedure 7 days after the first dose.

Study on Animal Reference Vaccine of Inactivated Rabies Vaccines for Potentcy Test

DEVELOPMENT OF AN ANTIRABIC REFERENCE VACCINE FROM THE RABIES VIRUS, STRAIN "SHCHELKOVO-51"

Evaluation and Correlation of Rabies Vaccine Potency Using the National Institute of Health, Rapid Focus Fluorescent Inhibition, and Passive Hemagglutination Tests

Validation Test on Inactivation of Rabies Vaccine: Development of Cell Culture Method

Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approach

Establishment and application of a noval CVS-11 pseudovirus-based assay for detection of neutralizing antibody against rabies virus

Development and evaluation of a new immunohistochemistry-based test for the detection of rabies virus neutralizing antibodies

Rapid fluorescent focus inhibition test optimization and validation: Improved detection of neutralizing antibodies to rabies virus

An Epidemiological Study of Rabies Virus in Domestic Dogs, Cats and Wildlife and the Immunogenicity Study for Rabies Vaccines Derived from Different Cell Cultured Virus Strains

Review of Detection and Quantification of Rabies Virus Antibodies.

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Rabies Virus Glycoprotein Serology ELISA for Measurement of Neutralizing Antibodies in Sera of Vaccinated Human Subjects.

Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system

Comparative Study on the Detection of Neutralizing Antibodies Against Rabies by Means of Mouse Neutralization Test and Rapid Fluorescent Focus Inhibition Test

Establishment of the Sixth Generation of National Standard for Potency Assay of Pertussis Vaccine

Immunogenicity Persistence of Different Immunization Regimens of Rabies Vaccine in the 10–60 Years Age Group: A Follow-Up Report Based on Phase III Clinical Trial

Immunogenicity and immune persistence of Zagreb 2-1-1 regimen of rabies vaccine in Chinese healthy individuals: A randomized, parallel-controlled of homologous vaccine with different immune procedure study

Study on Immune Persistence of the CTN-1V Strain Rabies Vaccine in Humans

Promising Rabies Vaccine for Postexposure Prophylaxis in Developing Countries, a Purified Vero Cell Vaccine Produced in China.

Characterization Of A Human Antibody Fragment Fab And Its Calcium Phosphate Nanoparticles That Inhibit Rabies Virus Infection With Vaccine

A Randomized, Double-Blind, Controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of a Lyophilized Human Rabies Vaccine (Vero Cells) in Healthy Participants Aged 10–60 Years Following Essen and Zagreb Vaccination Procedures